ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis ...( FREDERICK Md. May 14 /- ImQuest Bio...),Health
FREDERICK, Md., May 14 /PRNewswire/ -- ImQuest Bio and Arisyn jointly presented important new results on ATI-0810 (Formerly PG301029), a novel late stage inhibitor of hepatitis C virus (HCV) replication, at the 13th ISVHLD meeting held last week in Washington D.C. The presentation highlighted the ability of PG301029 to potently suppress the replication of HCV in vitro and defined its potential mechanism of antiviral action through the selection of a replicon resistant to the antiviral effects of the compound. Resistant HCV replicon sequences were selected in cell culture and resulted in mutations in the viral NS5A proximal to the NS5A-NS5B cleavage junction. The defined mutation would affect viral polyprotein processing at this site, or the interaction of NS5A, or the NS5A/5B polyprotein(s) with host cell factors involved in viral RNA replication, either of which presents a novel target for antiviral therapy. Todd B. Parsley, Ph.D., Director of Hepatitis Virus Research, presented the new findings which also included gene profiling patterns in compound treated and untreated cells. The studies included ImQuest co-authors Lu Yang, MD and Robert W. Buckheit, Jr., Ph.D.
"The data presented indicate that PG301029 has a unique mechanism of action as an inhibitor of hepatitis C virus replication," said the study's Principal Investigator, Dr. Parsley. "The genetic analysis suggests that PG301029 functions through a novel antiviral target, and we are excited about the prospects for exploiting this target for the development of new and potent anti-HCV therapies."
The presentation represents a continuation of the research partnership between ImQuest and Arisyn for the development of Arisyn's portfolio of antiviral and anticancer products based on its platform technology involving targeting of RNA transcription. Funding for the study was obtained in part from a Small Business SBIR grant recently awarded to ImQuest by th
'/>"/>
| SOURCE ImQuest BioSciences Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
2. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
3. ImQuest Presentations at Keystone Symposium Focus on Advancements in Their Therapeutic and Microbicide Development Programs
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
6. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |